Inventia Healthcare Limited is recalling 11,460 bottles of Chlorthalidone Tablets USP, 25 mg, a blood pressure medication distributed nationwide after the product failed dissolution specifications.
The recall was initiated June 5 and was classified as a Class II recall by the FDA on June 22, according to a June 22 enforcement report. The recall affects 100-tablet and 1,000-tablet bottles from two lots with expiration dates of April 2027.
Chlorthalidone is a diuretic used to treat high blood pressure and can also reduce swelling related to heart, kidney, or liver disease. Failed dissolution specifications mean the tablets may not dissolve properly in the body, potentially affecting how the drug’s active ingredients are absorbed.
Inventia Healthcare Limited manufactured the product. Rising Pharma Holdings distributed it in the U.S.
The recall comes roughly a month after another blood pressure medication — Amlodipine and Olmesartan Medoxomil tablets — was recalled in May for the same reason, also classified as a Class II recall.
Patients who believe they may have an affected bottle should consult their pharmacist or physician before stopping any prescribed medication.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
